Easy Find It Page
Easy Find It
Use Our Mobile Site
Use Our Mobile Site
Share This Website
The Sugar Trehalose
Free NEWS Letter
Affiliate Program
Untitled Document

Already an Affiliate? Click on the link below to access your account-

Affiliate Login

Endowment Book Store
The Trehalose Store
Endowment Store Front
Support The Endowment
Enter Amount:
We Accept
VisaMaster CardAmerican ExpressDiscoverssl lock
Download Store

Download Store

Download 7 Free Newsletters Plus Other Educational Materials

Main Menu
Home
- - - - - - -
Inside the Human Cell
The Sugar Trehalose
- - - - - - -
Sugar Science Forum
Glycomics Training
Interactive Glycomics Brochure
NEWS
7 FREE NEWSletters
HOT Links of Interest
- - - - - - -
Contact Us
Disclaimer
Sitemap
Educational e-textbook
Chapter One

Chapter One

FREE Sneek Peek
Chapter One


Evaluation Forms

Huntington’s General
Health Evaluation
FORM for Trehalose
Nutritional Pilot Survey

Parkinson's General
Health Evaluation
FORM for Trehalose
Nutritional Pilot Survey

Alzheimer / Dementia
General Health Evaluation
FORM for Trehalose
Nutritional Pilot Survey

Diabetic Health Evaluation
FORM for Trehalose
Nutritional Pilot Survey

General Public Health
Evaluation FORM for
Trehalose Nutritional
Pilot Survey (For General
Public without Huntington’s,
Alzheimer’s, or Parkinson’s.)

Who's Online
We have 124 guests online
Is There An Alzheimer's Diabetes Link?

Alzheimer's Theory Set for Drug Test

 WASHINGTON - A provocative new theory suggests that one root cause of Alzheimer's disease is linked to diabetes — a theory about to be tested in thousands of Alzheimer's patients given the diabetes drug Avandia in hopes of slowing brain decay.

t's a scary scenario: Alzheimer's already is expected to skyrocket as the population grays, rising from 4.5 million sufferers today to a staggering 14 million by 2050. If the new theory is right, the nation's current obesity-fueled epidemic of Type 2 diabetes could worsen that toll.

But proponents see potential good news: If diabetic-like changes in the way brain cells use sugar to generate energy truly trigger Alzheimer's in at least some patients, then maybe doctors could intervene early and slow down that degeneration.

A preliminary experiment involving 511 Alzheimer's patients found signals that Avandia might help — albeit in people who lack a gene that spurs more aggressive Alzheimer's.

Those results, combined with other evidence that the diabetes pathway is important, have Avandia maker GlaxoSmithKline poised to open three Phase III clinical trials this summer to test whether the diabetes drug, also called rosiglitazone, might protect certain patients' brains.

Diabetes has long been listed a risk factor for Alzheimer's later in life because it damages blood vessels that supply the brain.

The Avandia research suggests a more insidious connection: that Alzheimer's can be silently triggered when brain cells can't properly use their main fuel, sugar — just as Type 2 diabetes is triggered when insulin gradually loses its ability to process sugar body-wide.

"When they're in an insulin-resistant state, it does not just affect the body, it affects the brain as well," explains Suzanne Craft of the Veterans Affairs Puget Sound Health Care System, who led the initial research.

There are 18 million Type 2 diabetics, considered to have two to five times a non-diabetic's risk of developing Alzheimer's — if they live long enough, into the 60s and 70s when Alzheimer's typically strikes, Craft says. Type 2 diabetes often leads to heart disease or other ailments that kill before then.

Avandia, and the competing drug Actos, treat Type 2 diabetes by resensitizing the body to insulin.

Don't use Avandia for Alzheimer's until that question is settled, cautions Glaxo's Allen Roses, a highly regarded Alzheimer's researcher who, before joining the pharmaceutical company, discovered the brain disease's main genetic link.

He published the diabetes hypothesis in the medical journal Alzheimer's & Dementia last week.

If it pans out, "one thing we can do is, possibly, slow down the onset of the disease showing up," Roses says. But for now, "it's a hopeful experiment that's in progress."

Yet it's generating intense interest.

"This is an exciting new approach," Yadong Huang of the University of California, San Francisco, wrote in an accompanying review of Roses' hypothesis, which is backed by genetics research from Huang's own lab.

"I don't think this is hype for rosiglitazone," adds Dr. Sam Gandy, director of the Farber Institute for Neurosciences at Philadelphia's Thomas Jefferson University and an Alzheimer's Association spokesman. "This does dovetail with some existing knowledge."

No one knows what causes Alzheimer's creeping brain degeneration. Today's drugs only temporarily help symptoms. Now, researchers are hunting new ones that target the disease's hallmark, a sticky gunk called beta-amyloid that clogs up, and probably kills, neurons.

The new theory: The metabolism of neurons' internal power factors, called mitochondria, go awry so that those cells don't use enough sugar. That eventually leads to impaired brain cell function, including the buildup of that gunky beta-amyloid. It also means that neurons in youth and middle age don't sprout enough communication connections, providing less "cognitive reserve" once their neurons start dying off.

Among the evidence Roses cites:

_Decades before dementia symptoms begin, PET scans of people who carry an Alzheimer's-linked gene show their brain cells underuse sugar.

_Mice engineered to develop Alzheimer's-like disease experience the metabolism changes before beta-amyloid plaques appear — and insulin-sensitizing drugs enhance their brains' sugar use.

_Researchers who tracked 140,000 diabetic veterans found those who received insulin-resensitizing drugs were less likely to be diagnosed with Alzheimer's years later.

Then there's that preliminary Avandia study. Alzheimer's patients showed modest improvement in cognitive function — unless they carried the Alzheimer's-linked gene called ApoE4 that spurs more aggressive disease. The new studies will try to prove if that benefit was real.

___

EDITOR'S NOTE — Lauran Neergaard covers health and medical issues for The Associated Press in Washington.

Source